Diego M Capibaribe, Natalia D Avilez, Natássia C C Truzzi, José C C I Truzzi, Mehrsa Jalalizadeh, Leonardo O Reis
{"title":"超过 48,000 次年轻男性前列腺特异性抗原基线测量:16 年的时间分析。","authors":"Diego M Capibaribe, Natalia D Avilez, Natássia C C Truzzi, José C C I Truzzi, Mehrsa Jalalizadeh, Leonardo O Reis","doi":"10.5173/ceju.2024.62.R2","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To broaden our understanding of baseline PSA variations over the last decades in men under 40 years old.</p><p><strong>Material and methods: </strong>We analysed the baseline total PSA of 48,896 men below the age of 40 years, grouped into 3 age groups: <30 (n = 6,123), 30-35 (n = 16,118), and >35 (n = 25,351) years old. Multiple linear regression model predicted the average LogPSA per month as a function of time, age, and testing rate during the 16-year period of the data (2003-2018).</p><p><strong>Results: </strong>The average age and standard deviation were 34.5 ±4.6 years, and the median PSA ± interquartile range was 0.63 ±0.46 ng/dl with a leftward skew towards zero (81% of results below 1 ng/dl) in all years. The average LogPSA was steadily rising over time, independent of age and testing rate in all 3 age groups: multiple R<sup>2</sup> = 0.40, estimate = 1.211e-05, p <0.0001. Mean/median PSA and age were 0.69/0.57 ng/dl and 35.6/37.2 years in 2003 and 1.04/0.66 ng/dl and 33.6/35.8 years in 2018.</p><p><strong>Conclusions: </strong>The average baseline PSA is rising in young men. Changes in medical routine practice (e.g. reserving the test for those with higher suspicion) and a true rise in benign or pathological prostate conditions are possible reasons.</p>","PeriodicalId":9744,"journal":{"name":"Central European Journal of Urology","volume":"77 3","pages":"411-417"},"PeriodicalIF":1.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921936/pdf/","citationCount":"0","resultStr":"{\"title\":\"Over 48,000 baseline prostate-specific antigen measurements in young men: a 16-year time-analysis.\",\"authors\":\"Diego M Capibaribe, Natalia D Avilez, Natássia C C Truzzi, José C C I Truzzi, Mehrsa Jalalizadeh, Leonardo O Reis\",\"doi\":\"10.5173/ceju.2024.62.R2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>To broaden our understanding of baseline PSA variations over the last decades in men under 40 years old.</p><p><strong>Material and methods: </strong>We analysed the baseline total PSA of 48,896 men below the age of 40 years, grouped into 3 age groups: <30 (n = 6,123), 30-35 (n = 16,118), and >35 (n = 25,351) years old. Multiple linear regression model predicted the average LogPSA per month as a function of time, age, and testing rate during the 16-year period of the data (2003-2018).</p><p><strong>Results: </strong>The average age and standard deviation were 34.5 ±4.6 years, and the median PSA ± interquartile range was 0.63 ±0.46 ng/dl with a leftward skew towards zero (81% of results below 1 ng/dl) in all years. The average LogPSA was steadily rising over time, independent of age and testing rate in all 3 age groups: multiple R<sup>2</sup> = 0.40, estimate = 1.211e-05, p <0.0001. Mean/median PSA and age were 0.69/0.57 ng/dl and 35.6/37.2 years in 2003 and 1.04/0.66 ng/dl and 33.6/35.8 years in 2018.</p><p><strong>Conclusions: </strong>The average baseline PSA is rising in young men. Changes in medical routine practice (e.g. reserving the test for those with higher suspicion) and a true rise in benign or pathological prostate conditions are possible reasons.</p>\",\"PeriodicalId\":9744,\"journal\":{\"name\":\"Central European Journal of Urology\",\"volume\":\"77 3\",\"pages\":\"411-417\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921936/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Central European Journal of Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5173/ceju.2024.62.R2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central European Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5173/ceju.2024.62.R2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Over 48,000 baseline prostate-specific antigen measurements in young men: a 16-year time-analysis.
Introduction: To broaden our understanding of baseline PSA variations over the last decades in men under 40 years old.
Material and methods: We analysed the baseline total PSA of 48,896 men below the age of 40 years, grouped into 3 age groups: <30 (n = 6,123), 30-35 (n = 16,118), and >35 (n = 25,351) years old. Multiple linear regression model predicted the average LogPSA per month as a function of time, age, and testing rate during the 16-year period of the data (2003-2018).
Results: The average age and standard deviation were 34.5 ±4.6 years, and the median PSA ± interquartile range was 0.63 ±0.46 ng/dl with a leftward skew towards zero (81% of results below 1 ng/dl) in all years. The average LogPSA was steadily rising over time, independent of age and testing rate in all 3 age groups: multiple R2 = 0.40, estimate = 1.211e-05, p <0.0001. Mean/median PSA and age were 0.69/0.57 ng/dl and 35.6/37.2 years in 2003 and 1.04/0.66 ng/dl and 33.6/35.8 years in 2018.
Conclusions: The average baseline PSA is rising in young men. Changes in medical routine practice (e.g. reserving the test for those with higher suspicion) and a true rise in benign or pathological prostate conditions are possible reasons.